A meta-analysis of over 68,000 patients found that PCSK9 inhibitors did not increase the short-term risk of developing type 2 diabetes. However, exploratory analyses suggested a trend towards increased risk in patients with intense LDL cholesterol reduction and long-term treatment.
A common genetic variant in the LILRB5 gene is associated with an increased risk of muscle aches and statin intolerance. Researchers found that individuals carrying two copies of this variant have a higher risk of general statin intolerance and low-dose intolerance, highlighting the need for alternative treatment options.
Atrial fibrillation (AF) is a common heart arrhythmia that can lead to strokes. The REHEARSE-AF trial found that twice-weekly ECG recording by patients increased AF diagnosis in patients with stroke risk factors, suggesting the potential to reduce strokes through earlier treatment.
The REVEAL trial found that anacetrapib significantly reduces the incidence of major coronary events and improves HDL cholesterol levels, while also reducing LDL cholesterol by at least 20%
A new study analyzing data from the Swedish Coronary Angiography and Angioplasty Registry found no significant benefits of pre-hospital antiplatelet therapy in STEMI patients. The study suggests that pre-treatment may even pose a risk, particularly for patients with contraindications to antithrombotic therapy.
A large study found that high carbohydrate intake is linked to increased total mortality and non-cardiovascular mortality outcomes, while high fat intake is associated with lower risk. The study suggests that limiting total fat consumption may not improve health in populations.
The CHANGE-DAPT trial found that following contemporary guidelines for dual anti-platelet therapy may not be preferable to older guidelines in reducing ischemic events, but increases major bleeding risk. Newer-generation drug-eluting stents have shifted the risk-benefit balance of ticagrelor in ACS patients undergoing PCI.
A large-scale study of 135,335 individuals across 18 countries found that a moderate intake of fruit, vegetables, and legumes can significantly reduce the risk of cardiovascular disease and death. The study's findings indicate that consuming an average of 3-4 servings per day is as beneficial as higher amounts in reducing total mortality.
The HCM-EVIDENCE study validates ESC recommendations for predicting and preventing sudden cardiac death in patients with hypertrophic cardiomyopathy. The risk prediction tool, HCM Risk-SCD, accurately distinguishes between high- and low-risk patients, with good agreement between predicted and actual SCD rates.
A Japanese study questioned the benefit of treat-to-target intensive statin therapy in patients with diabetic retinopathy, finding no significant reduction in cardiovascular events. However, subanalysis showed that reaching an LDL cholesterol target of less than 70 mg/dL significantly reduced primary endpoint incidence.
A study found that dark chocolate enriched with extra virgin olive oil is associated with increased endothelial progenitor cells and decreased carnitine levels, leading to improved cardiovascular health. The addition of natural polyphenols from olive oil also increased high-density lipoprotein cholesterol and decreased blood pressure.
A new prediction tool has been developed to identify elderly patients at greatest risk of acute myocardial infarction during Asian dust storms. The tool, based on a simple scoring system, takes into account various pre-existing conditions and can help prevent AMI in high-risk patients.
The CAPTAF trial found that ablation of atrial fibrillation significantly improved quality of life and general health compared to antiarrhythmic drug therapy. Ablation was also shown to reduce symptoms and improve quality of life in patients with paroxysmal and persistent AF.
Researchers found that PCSK9 inhibition can reverse the effects of oxidised LDL on immune activation, leading to an anti-inflammatory state that may directly influence atherosclerosis and cardiovascular disease. This new mechanism is independent of lowering LDL cholesterol.
A study found that ibuprofen, a commonly prescribed NSAID, increases blood pressure and is associated with a higher incidence of hypertension in patients with osteoarthritis or rheumatoid arthritis. Celecoxib, on the other hand, showed a slight decrease in blood pressure, while naproxen had a relatively small increase.
A study found that sildenafil increased the risk of hospitalization and death in patients with valvular heart disease and residual pulmonary hypertension. The drug should be avoided in these cases.
New research suggests that anti-aldosterone-type drugs can significantly increase survival rates in STEMI heart attack patients when used alongside standard therapy. The study pooled data from two trials and found a 60% reduction in deaths among MRA-treated patients compared to controls.
A novel screening programme for vascular disease saves one life for every 169 men assessed. The combined screening for abdominal aortic aneurysm, peripheral artery disease, and hypertension gained more living years for lower costs than European cancer screening programmes.
Nonagenarian patients undergoing TAVI had worse short-term outcomes but similar one-year clinical outcomes as younger patients. The study suggests that TAVI is safe and effective in elderly patients with aortic stenosis.
A large clinical trial found that oxygen therapy did not reduce mortality rates in patients with suspected myocardial infarction. The study enrolled over 6,200 patients and showed no significant difference in mortality rates between those who received oxygen and those who did not.
The IMPACT-AF trial found that education and feedback improved anticoagulation therapy adherence in atrial fibrillation patients. This resulted in a 9% absolute increase in anticoagulation use, with a 48% proportion of non-treated patients on medication in the intervention group.
A 3-year follow-up study shows that a short course of dual antiplatelet therapy is as beneficial as a longer course for patients who received a drug-eluting stent. The study found no significant differences in rates of cardiac events and major bleeding between those treated for 6 versus 18 months.
A minimally invasive catheter-based procedure lowered office and ambulatory blood pressure in uncontrolled hypertensive patients not taking medication. Renal denervation was effective in reducing blood pressure, even with small reductions correlating to significant cardiovascular risk reductions.
A recent study found that the clinical benefit of LDL cholesterol lowering therapies depends on how it is lowered, with apoB particles playing a key role. The study used genetically randomized participants and found that reducing apoB levels had a greater impact on cardiovascular risk than reducing LDL cholesterol.
A new study published by the European Society of Cardiology found that bag-mask ventilation does not improve survival rates compared to endotracheal intubation in out-of-hospital cardiac arrest patients. The trial included 2,043 patients and showed a higher incidence of failed ventilation with bag-mask ventilation.
A post-hoc analysis of the SPRINT trial suggests that a universal blood pressure target may not be suitable for all patients. For those with high systolic blood pressure readings, intensive treatment might not always be beneficial, and the harms of aggressive treatment could outweigh the benefits.
The PATHWAY-2 study finds that salt retention is the main cause of drug-resistant hypertension and that older diuretic medications are the most effective treatment. The research discovered that spironolactone and amiloride work equally well in lowering blood pressure, offering new alternatives for patients with resistant hypertension.
The EMANATE trial shows that apixaban lowers stroke risk in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion. Patients treated with apixaban had fewer strokes than those receiving usual care, with similar bleeding rates to warfarin.
The study found that closure of the left atrial appendage during open heart surgery significantly reduces the risk of stroke and silent cerebral infarctions. Patients who underwent surgical closure had a lower cumulative probability of an ischaemic event in the brain compared to those without closure.
A 16-year study of over 280,000 patients found that colder air temperatures are associated with a higher risk of heart attacks. The study, led by Prof David Erlinge from Lund University, used meteorological data to analyze the relationship between weather conditions and heart attack incidence.
A new study published at ESC Congress shows that blood pressure variability is strongly associated with adverse outcomes in patients with atrial fibrillation. The study found that consistency in blood pressure control is vital, regardless of patient age or blood pressure level.
The ORION 1 trial shows inclisiran lowers LDL cholesterol by -31.6% and -46.8% at one year with single and two dose regimens, respectively. The two dose regimen produced the greatest reductions in LDL cholesterol without side effects.
A new analysis of the FOURIER trial found that very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with fewer cardiovascular events without increased safety risks. The study suggested that lowering LDL-C levels below current guidelines can further reduce recurrent cardiovascular events in high-risk patients.
Researchers found that married patients who have had a heart attack are 14% more likely to survive compared to single patients. Marriage also provides protection for patients with high cholesterol, diabetes, and high blood pressure, increasing their chances of survival by 16%, 14%, and 10%, respectively.
A 14-year study found that statins reduce breast cancer risk by 45% and mortality risk by 40%. Women with high cholesterol had significantly lower breast cancer rates and improved survival rates compared to those without high cholesterol.
A new study found that higher coffee consumption is associated with a lower risk of death, particularly among those aged 45 and above. Drinking four cups of coffee per day was linked to a 64% reduced risk of all-cause mortality.
A new study has confirmed the safety and efficacy of a rapid algorithm to rule-out and rule-in myocardial infarction. The algorithm uses high-sensitivity cardiac troponin blood concentrations to diagnose patients with acute chest pain, allowing for quicker triage and early initiation of evidence-based therapy.
The CANTOS trial found that canakinumab significantly reduced the risk of cardiovascular events and total cancer death, with dose-dependent effects on lung cancer rates. The study showed a 15% reduction in cardiovascular event risk and a 17% reduction in hospitalization for unstable angina.
A new study, CASTLE-AF, shows that catheter ablation significantly improves outcomes for patients with left ventricular dysfunction and atrial fibrillation. The treatment reduces the risk of stroke, blood clots, and heart failure in these patients.
The COMPASS trial found that the combination of rivaroxaban and aspirin reduces major adverse cardiovascular and limb events by 31%, lowering cardiovascular death, stroke or heart attack by 28% and limb-threatening ischaemia by 46%. Rivaroxaban alone does not reduce major adverse cardiovascular events but lowers major adverse limb events.
The RACE 3 trial found that risk factor-driven upstream rhythm control is effective in improving maintenance of sinus rhythm in patients with early short-lasting AF and heart failure. Sinus rhythm was present in 75% of patients in the upstream therapy group compared to 63% in the control group.
The COMPASS trial found that combining rivaroxaban and aspirin improved survival by 18% and reduced cardiovascular death, stroke, or heart attack by 24%. The treatment also increased bleeding risk but showed significant net benefits for patients.
A study by Progetto Vita found that 93% of patients treated with an onsite AED survived cardiac arrest, compared to just 9% without an AED. The presence of an AED significantly reduced response times and improved survival rates.
A new study published in the European Society of Cardiology found that high salt intake is associated with a doubled risk of heart failure. The study, which followed over 4,000 participants for 12 years, estimated individual salt intake using a 24-hour sodium extraction method.
Research suggests PCSK9 plays a role in platelet activation and aggregation, with higher levels linked to increased platelet reactivity. PCSK9 inhibitors may also reduce thrombosis by interfering with platelet function.
A recent study found that women at high risk of cardiovascular events are more likely to receive lower doses and less potent statin treatments, which can increase the risk of preventable events. According to the DYSIS study, women were 32% less likely to reach the recommended LDL cholesterol target compared to men.
Underweight patients undergoing cardiac catheterisation are more likely to die, experience longer hospital stays, and incur higher costs compared to normal weight or obese patients. Morbidly obese patients, on the other hand, have better outcomes despite having a lower BMI.
The guidelines introduce a clear definition of when to start the clock for percutaneous coronary intervention, recommending vessel opening within 90 minutes from STEMI diagnosis. The document also updates recommendations on medications, PCI access, and fibrinolysis, emphasizing the importance of timely treatment.
The ESC Focused Update provides recommendations for dual antiplatelet therapy (DAPT) in patients with coronary artery disease. DAPT reduces the risk of acute to very late stent thrombosis, but the optimal duration is uncertain. The Task Force recommends a personalized approach based on ischaemic versus bleeding risks.
The ESC Guidelines provide comprehensive recommendations for the diagnosis and treatment of peripheral arterial diseases, affecting over 40 million Europeans. Key findings include revised guidelines for revascularization of asymptomatic carotid stenosis and a strong recommendation against systematic revascularisation of renal stenosis.